Results 31 to 40 of about 3,056 (181)

Real-world evidence for amyloid-targeted therapies: Lecanemab and donanemab. [PDF]

Alzheimers Dement (Amst)
INTRODUCTION Real‐world safety data on amyloid‐targeted therapies in early Alzheimer's disease remain limited, particularly for modified donanemab titration and direct lecanemab–donanemab comparisons.
Hakim R, Harris K, Merrill L, Falk-Vargas A, Whalen E, Xia T, Ochoa O, Hunter D, Schulz PE.   +8 more
europepmc   +2 more sources

Donanemab exposure‐response in early symptomatic Alzheimer's disease

Alzheimer's and Dementia
Abstract INTRODUCTION These analyses aimed to identify factors impacting donanemab exposure, amyloid plaque, and clinical efficacy in early symptomatic Alzheimer's disease using a population pharmacokinetic/pharmacodynamic (PK/PD) approach.
Gueorguieva, Ivelina, Chow, Kay, Chua, Laiyi, Shcherbinin, Sergey, Zimmer, Jennifer A., Evans, Cynthia D., Wang, Hong, Nery, Emel Serap Monkul, Brooks, Dawn A., Sims, John R.   +9 more
exaly   +3 more sources

Correction to "Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application". [PDF]

Chronic Dis Transl Med
Chronic Diseases and Translational Medicine, EarlyView.
europepmc   +2 more sources

Plasma P-tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease. [PDF]

Alzheimers Dement
INTRODUCTION This analysis of the phase 3 TRAILBLAZER‐ALZ 2 trial examined whether plasma tau protein phosphorylated at threonine 217 (p‐tau217) level can reliably monitor treatment‐related amyloid clearance (TRAC) after donanemab ...
Collins EC, Lu M, Beck R, Hendrix J, Hodsdon ME, Hansson O.   +5 more
europepmc   +2 more sources

Experience with donanemab over a 1-year period: observations of side effects and compliance from a regional specialty medical center. [PDF]

Alzheimers Dement (Amst)
INTRODUCTION The anti‐amyloid monoclonal antibody donanemab (Kisunla™) treats patients with mild cognitive impairment or mild Alzheimer's disease.
Shields LBE, Hust HS, Cooper GE, Kluthe T, Hart RN, Thaliath AP, Dennis BC, Freeman SW, Cain JF, Shang WY, Wasz KM, Orr AT, Shields CB, Barve SS, Pugh KG.   +14 more
europepmc   +2 more sources

Donanemab in Early Symptomatic Alzheimer Disease : The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

, 2023
Importance: There are limited efficacious treatments for Alzheimer disease. Objective: To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque.
Ardayfio, Paul, Mintun, Mark,, Monkul Nery, Emel Serap,, Shcherbinin, Sergey,, Solomon, Paul,, Lu, Ming,, Evans, Cynthia D., Apostolova, Liana G., Wessels, Alette M.,, Solomon, Paul, Hansson, Oskar, Brooks, Dawn A.,, Ritchie, Craig, Sims, John R.,, Monkul Nery, Emel Serap, Apostolova, Liana G.,, Hansson, Oskar,, Brooks, Dawn A., Salloway, Stephen, Mintun, Mark, Lu, Ming, Salloway, Stephen,, TRAILBLAZER-ALZ 2 Investigators, Zimmer, Jennifer A.,, Evans, Cynthia D.,, Sims, John R., Zimmer, Jennifer A., Skovronsky, Daniel M., Ardayfio, Paul,, Shcherbinin, Sergey, Sparks, Jon David, Wang, Hong,, Collins, Emily C., Sparks, JonDavid, Sparks, Jon David,, Wang, Hong, Collins, Emily C.,, Skovronsky, Daniel M.,, Wessels, Alette M., Lund University.   +39 more
core   +2 more sources

Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial. [PDF]

Neurol Clin Pract
Background and objectives: Understanding the meaningfulness of clinical trial outcomes is essential for people living with Alzheimer disease (AD) and their clinicians to make evidence-based shared treatment decisions in real-world clinical care ...
Atri A, Apostolova LG, Iwata A, Wessels AM, Atkins A, Lu M, Ye W, Ryan S, Doty EG.   +8 more
europepmc   +2 more sources

Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review. [PDF]

J Clin Med
Background: Over the last decade, numerous studies have investigated the administration of monoclonal anti-amyloid antibodies (AAAs) as a therapeutic approach in Alzheimer’s disease (AD).
Kalampokini S, Keramidiotis I, Frontistis A, Zuchi F, Michmizos D, Papaliagkas V, Koutsouraki E.   +6 more
europepmc   +2 more sources

Further data to address the Alzheimer's coverage with evidence development questions. [PDF]

Alzheimers Dement
INTRODUCTION Medicare patients currently access amyloid‐targeting therapies for Alzheimer's disease through the class‐based National Coverage Determination (NCD) with coverage with evidence development (CED) established in 2022 ...
Boustani M, Klein EG, Zimmer JA, Wang H, Engle SE, Phipps A, Japha M, Schilling T, Hartry A, Alzheimer's Disease Neuroimaging Initiative.   +9 more
europepmc   +2 more sources

Donanemab: Not two without a third

Advances in Clinical and Experimental Medicine, 2023
Recently, the U.S. Food and Drug Administration (FDA) approved 2 anti-amyloid monoclonal antibodies, aducanumab (June 7, 2021) and lecanemab (July 6, 2023), for the treatment of Alzheimer's disease (AD) patients, and will most likely also approve a 3rd one, donanemab, soon.
openaire   +2 more sources